BioCentury | Feb 10, 2017
Company News

GenomeDx, Astellas deal

...Phase II ENACT trial, which is evaluating Xtandi vs. active surveillance. GenomeDx will use its Decipher Prostate Cancer Classifier...
BioCentury | Feb 9, 2015
Company News

GenomeDx Biosciences sales and marketing update

...administrative contractor Palmetto GBA issued a positive coverage policy through its MolDX Program for GenomeDx’s Decipher Prostate Cancer Classifier...
BioCentury | Oct 20, 2014
Clinical News

Decipher Prostate Cancer Classifier regulatory update

...administrative contractor Palmetto GBA issued a draft local coverage determination (LCD) recommending coverage for GenomeDx's Decipher Prostate Cancer Classifier...
...Clinic (Rochester, Minn.) (see BioCentury, May 6, 2013). GenomeDx Biosciences Inc. , Vancouver, B.C. Product: Decipher Prostate Cancer Classifier...
BioCentury | Jun 23, 2014
Company News

GenomeDx Biosciences Inc sales and marketing update

...GenomeDx said U.S. healthcare PPO network Prime Health Services Inc. will cover GenomeDx’s Decipher Prostate Cancer Classifier. GenomeDx markets...
BioCentury | Feb 18, 2013
Clinical News

Decipher test diagnostic data

...An analysis of 219 prostate cancer patients who underwent radical prostatectomy showed that GenomeDx Biosciences' Decipher test...
...to predict prostate cancer metastasis after radical prostatectomy. GenomeDx Biosciences Inc. , Vancouver, B.C. Product: Decipher test...
Items per page:
1 - 5 of 5